Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY

20260 citationsJournal Articlehybrid Open Access

Authors

Paul Madley‐Dowd · University Hospitals Bristol NHS Foundation Trust

Elsie M.F. Horne · University Hospitals Bristol NHS Foundation Trust

William J. Hulme · University of Oxford

Tom M. Palmer · Bristol City Council

Venexia Walker · University of Bristol

Rachel Denholm · University Hospitals Bristol NHS Foundation Trust

Jonathan A.C. Sterne

Abstract

Rates of COVID-19-related hospitalisation and death were substantially lower after bivalent original/omicron BA.1 mRNA booster vaccine than in people who remained unboosted. Apparent protection against fracture suggests some unmeasured confounding. Outcomes appeared similar for the Moderna and Pfizer-BioNTech vaccines.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Intramuscular injections and effects Lymphadenopathy Diagnosis and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Vaccine

Volume 76, pp. 128276-128276

DOI: 10.1016/j.vaccine.2026.128276

Field-Weighted Citation Impact: 0.00